Cushing's Disease With Cortisol Overproduction Therapeutics
1. Isturisa patent expiration
Treatment: Treatment of endogenous hypercortisolemia in adults with cushing's syndrome for whom surgery is not an option or has not been curative
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9434754 | RECORDATI RARE | Use of an adrenal hormone-modifying agent |
Jan, 2031
(4 years from now) | |
| US8835646 | RECORDATI RARE | Organic compounds |
Aug, 2026
(a month from now) | |
| US8314097 | RECORDATI RARE | Organic compounds |
May, 2033
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8609862 | RECORDATI RARE | Use of an adrenal hormone-modifying agent |
Jan, 2031
(4 years from now) | |
| US10143680 | RECORDATI RARE | Pharmaceutical dosage forms |
Jul, 2035
(9 years from now) | |
| US10709691 | RECORDATI RARE | Pharmaceutical dosage forms |
Oct, 2035
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 06, 2025 |
| Orphan Drug Exclusivity(ODE-286) | Mar 06, 2027 |
| Orphan Drug Exclusivity(ODE-535) | Apr 15, 2032 |
Drugs and Companies using OSILODROSTAT PHOSPHATE ingredient
NCE-1 date: 06 March, 2024
Market Authorisation Date: 06 March, 2020
Dosage: TABLET
More Information on Dosage
ISTURISA family patents
